Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heparin is a naturally occurring glycosaminoglycan and widely used anticoagulant medication. It is primarily used to prevent and treat blood clots in conditions such as deep vein thrombosis, pulmonary embolism, heart attacks (myocardial infarction), unstable angina, and during medical procedures like open-heart surgery or dialysis[1][2][3][5]. Heparin works by binding to antithrombin III (ATIII), which accelerates the inactivation of several clotting factors—most notably thrombin (factor IIa) and factor Xa—thereby inhibiting the formation of fibrin clots[4][5][6]. This mechanism prevents new clots from forming or existing ones from growing but does not dissolve established clots. Heparin is administered intravenously or subcutaneously because it is not absorbed orally[8]. It has a rapid onset but short duration of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparin.